{"id":564017,"date":"2021-09-17T13:30:01","date_gmt":"2021-09-17T13:30:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=564017"},"modified":"2021-09-17T13:30:01","modified_gmt":"2021-09-17T13:30:01","slug":"overt-hepatic-encephalopathy-market-analysis-of-epidemiology-pipeline-products-and-key-companies-working","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/overt-hepatic-encephalopathy-market-analysis-of-epidemiology-pipeline-products-and-key-companies-working_564017.html","title":{"rendered":"Overt Hepatic Encephalopathy Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working"},"content":{"rendered":"
\n
\"Overt<\/a><\/div>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Overt Hepatic Encephalopathy – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Overt Hepatic Encephalopathy, historical and forecasted epidemiology as well as the Overt Hepatic Encephalopathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n

DelveInsight has launched a new report on “Overt Hepatic Encephalopathy – Market Insights, Epidemiology, and Market Forecast-2030”.<\/strong><\/p>\n

DelveInsight’s “Overt Hepatic Encephalopathy – Market Insights, Epidemiology, and Market Forecast-2030″ <\/a><\/strong>report delivers an in-depth understanding of the Overt Hepatic Encephalopathy, historical and forecasted epidemiology as well as the Overt Hepatic Encephalopathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

\"\"<\/p>\n

Some of the key facts of the Overt Hepatic Encephalopathy Market Report:<\/a><\/strong><\/p>\n

    \n
  1. \n

    Total diagnosed prevalent cases of Cirrhosis (hospitalized) in the 7MM was found to be 860,784 in 2020. These cases are expected to increase by 2030 at a CAGR of 0.63% during the study period (2018–2030).<\/p>\n<\/li>\n

  2. \n

    The diagnosed prevalent cases of Hepatic Encephalopathy in the 7MM are expected to increase at a CAGR of 0.61% for the study period of 2018-2030.<\/p>\n<\/li>\n

  3. \n

    Among 7MM, the United States has the highest diagnosed prevalent cases of hepatic encephalopathy with 205,018 cases in 2020. <\/p>\n<\/li>\n<\/ol>\n

    Key benefits of the report:<\/strong><\/p>\n

      \n
    1. \n

      Overt Hepatic Encephalopathy market report covers a descriptive overview and comprehensive insight of the Overt Hepatic Encephalopathy Epidemiology and Overt Hepatic Encephalopathy  market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/p>\n<\/li>\n

    2. \n

      The Overt Hepatic Encephalopathy market report provides insights on the current and emerging therapies.<\/p>\n<\/li>\n

    3. \n

      Overt Hepatic Encephalopathy market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/p>\n<\/li>\n

    4. \n

      The Overt Hepatic Encephalopathy market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Overt Hepatic Encephalopathy market.<\/p>\n<\/li>\n<\/ol>\n

      Got queries? Click here to know more about the Overt Hepatic Encephalopathy Market Landscape.<\/a><\/strong><\/p>\n

      Overt Hepatic Encephalopathy Overview<\/strong><\/p>\n

      Hepatic encephalopathy (HE) is a brain disorder that develops in some individuals with liver disease. HE presents as a spectrum of neuropsychiatric symptoms ranging from subtle fluctuating cognitive impairment to coma and is a significant contributor to morbidity in patients with liver disease. It is observed in acute liver failure, liver bypass procedures – for example, shunt surgery and trans-jugular intrahepatic portosystemic shunt – and cirrhosis, classified as Type A, B, and C HE, respectively. Pathogenesis is linked with ammonia and glutamine production. Treatment is based on mechanisms to reduce these compounds’ formation and\/or removal; many of the symptoms are reversible when promptly detected and treated.<\/p>\n

      Overt Hepatic Encephalopathy Market <\/strong><\/p>\n

      The dynamics of the Overt Hepatic Encephalopathy market<\/strong> is anticipated to change in the coming years owing to the expected launch of emerging therapies such as Salix Pharmaceuticals\/Bausch Health, Axcella Health, Inc., Vedanta Biosciences\/Patricia Bloom, and others during the forecasted period 2021-2030.<\/p>\n

      Learn more by requesting for sample @ Overt Hepatic Encephalopathy Market Landscape <\/a><\/strong><\/p>\n

      Overt Hepatic Encephalopathy Pipeline Therapies and Key Companies <\/strong><\/p>\n

        \n
      1. \n

        Rifaximin (SSD): Salix Pharmaceuticals\/Bausch Health<\/p>\n<\/li>\n

      2. \n

        AXA1665: Axcella Health, Inc.<\/p>\n<\/li>\n

      3. \n

        VE303: Vedanta Biosciences\/Patricia Bloom, and others<\/p>\n<\/li>\n<\/ol>\n

        Table of Contents<\/strong><\/p>\n

        1. Report Introduction<\/p>\n

        2. Executive Summary<\/p>\n

        3. SWOT analysis<\/p>\n

        4. Overt Hepatic Encephalopathy Patient Share (%) Overview at a Glance<\/p>\n

        5. Overt Hepatic Encephalopathy Market Overview at a Glance<\/p>\n

        6. Overt Hepatic Encephalopathy Disease Background and Overview<\/p>\n

        7. Overt Hepatic Encephalopathy Epidemiology and Patient Population<\/p>\n

        8. Country-Specific Patient Population of Overt Hepatic Encephalopathy <\/p>\n

        9. Overt Hepatic Encephalopathy Current Treatment and Medical Practices<\/p>\n

        10. Unmet Needs<\/p>\n

        11. Overt Hepatic Encephalopathy Emerging Therapies<\/p>\n

        12. Overt Hepatic Encephalopathy Market Outlook<\/p>\n

        13. Country-Wise Overt Hepatic Encephalopathy Market Analysis (2017–2030)<\/p>\n

        14. Market Access and Reimbursement of Therapies<\/p>\n

        15. Market drivers<\/p>\n

        16. Market barriers<\/p>\n

        17. Appendix<\/p>\n

        18. Overt Hepatic Encephalopathy Report Methodology<\/p>\n

        19. DelveInsight Capabilities<\/p>\n

        20. Disclaimer<\/p>\n

        21. About DelveInsight<\/p>\n

        Click here to read more about Overt Hepatic Encephalopathy Market Outlook 2030<\/a><\/strong> <\/p>\n

        Media Contact<\/span>
        Company Name:<\/strong>         DelveInsight Business Research LLP<\/a>
        Contact Person:<\/strong> Kritika Rehani
        Email:<\/strong>         Send Email<\/a>
        Phone:<\/strong> 9193216187
        Address:<\/strong>304 S. Jones Blvd #2432
        City:<\/strong> Las Vegas
        State:<\/strong> Nevada
        Country:<\/strong> United States
        Website:<\/strong>         https:\/\/www.delveinsight.com\/<\/a><\/p>\n

        <\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

        DelveInsight Business Research LLP DelveInsight’s “Overt Hepatic Encephalopathy – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Overt Hepatic Encephalopathy, historical and forecasted epidemiology as well as the Overt Hepatic Encephalopathy market trends in the … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-564017","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/564017","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=564017"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/564017\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=564017"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=564017"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=564017"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}